Now that the dust has settled on the Russell rebalancing - the annual reshuffle of the Russell indexes - biotech company ADC Therapeutics SA (ADCT) is making its debut in the widely followed Russell 2000 Index (RUT). Joining the RUT typically means increased volume, better liquidity, and more investor interest.
Despite being a penny stock, ADCT has Wall Street’s strong backing, with a “Strong Buy” rating and a mean target price that suggests the shares could nearly triple from current levels.
